journal article·2024-12-18

Tumor-Targeted Metal–Organic Framework for Improved Photodynamic Therapy and Inhibited Tumor Metastasis in Melanoma

Wenhao Gao, Yutong Song, Fei Wu, Shiting Xu, Bin Liu, Lingjun Zeng, Enqin Zheng, Hongtao Song, Qian Zhang

ACS Applied Materials & Interfaces· Volume 16· Issue 50
Publisher page

Abstract

Tumor hypoxia and elevated intracellular glutathione (GSH) levels significantly compromise the effectiveness of photodynamic therapy (PDT) in treating melanoma. In this study, we synthesized positively charged nanoparticles through a self-assembly method, incorporating photosensitizer verteporfin (VER), mitochondrial respiratory inhibitor atovaquone (ATO), and Fe 3+ . Subsequently, the nanoparticles were modified with sodium hyaluronate (HA) to obtain HA-ATO-Fe 3+ -VER nanoparticles (HAFV NPs). The fabricated HAFV NPs demonstrated excellent stability and in vitro Fenton reaction activity. HA facilitated the cellular internalization of HAFV NPs by targeting CD44 receptors, hence relieving tumor hypoxia through the disruption of the mitochondrial respiratory chain and involvement in the Fenton reaction. Simultaneously, ATO directly impeded the biosynthesis of GSH by diminishing ATP levels, while Fe 3+ was supposed to oxidate GSH to GSSG, thereby doubly depleting GSH. The integration of these multiple mechanisms markedly enhanced the PDT efficacy of VER. Following intravenous administration, HAFV NPs preferentially accumulated in tumor tissues with minimal accumulation in the skin, demonstrating favorable biocompatibility in vivo . Furthermore, HAFV NPs effectively inhibited tumor growth and lung metastasis, which presents a promising strategy for melanoma treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Metal-Organic Frameworks: Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, Fujian Medical University, Fuzhou 350122, China

Department of Pharmacy, The 900th Hospital of Joint Logistic Support Force PLA, Fuzhou 350025, China

Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China

Funding

Natural Science Foundation of Fujian Province

References (57)

Show source-provided references
1. 10.1172/jci.insight.15945210.1172/jci.insight.159452 ↗
2. 10.3390/ph1610139410.3390/ph16101394 ↗
3. 10.1038/s42003-021-01911-x10.1038/s42003-021-01911-x ↗
4. 10.1038/nrdp.2015.310.1038/nrdp.2015.3 ↗
5. 10.2147/IJN.S44904210.2147/IJN.S449042 ↗
6. 10.1016/j.cclet.2021.06.05310.1016/j.cclet.2021.06.053 ↗
7. 10.1039/D0NH00480D10.1039/D0NH00480D ↗
8. 10.3390/molecules2621653210.3390/molecules26216532 ↗
9. 10.1021/ja511420n10.1021/ja511420n ↗
10. 10.1007/s00604-021-04801-510.1007/s00604-021-04801-5 ↗
11. 10.1021/jacs.0c0073410.1021/jacs.0c00734 ↗
12. 10.1158/0008-5472.CAN-15-049110.1158/0008-5472.CAN-15-0491 ↗
13. 10.1002/1878-0261.1358310.1002/1878-0261.13583 ↗
14. 10.7554/eLife.6333310.7554/eLife.63333 ↗
15. 10.1038/s41591-018-0052-410.1038/s41591-018-0052-4 ↗
16. 10.1002/adhm.20210097810.1002/adhm.202100978 ↗
17. 10.1186/s12951-021-00827-210.1186/s12951-021-00827-2 ↗
18. 10.1016/j.ijpharm.2022.12157810.1016/j.ijpharm.2022.121578 ↗
19. 10.2147/IJN.S28351510.2147/IJN.S283515 ↗
20. 10.7150/thno.3286710.7150/thno.32867 ↗
21. 10.1021/acsami.9b0967110.1021/acsami.9b09671 ↗
22. 10.1016/j.jconrel.2023.12.05610.1016/j.jconrel.2023.12.056 ↗
23. 10.1016/j.addr.2008.06.00110.1016/j.addr.2008.06.001 ↗
24. 10.1038/s41420-020-00343-610.1038/s41420-020-00343-6 ↗
25. 10.1016/j.ijpharm.2023.12297010.1016/j.ijpharm.2023.122970 ↗
26. 10.2147/IJN.S40157010.2147/IJN.S401570 ↗
27. 10.2147/IJN.S39495310.2147/IJN.S394953 ↗
28. 10.1021/acs.molpharmaceut.3c0124310.1021/acs.molpharmaceut.3c01243 ↗
29. 10.1039/C9BM01646E10.1039/C9BM01646E ↗
30. 10.1021/acsnano.9b0030010.1021/acsnano.9b00300 ↗
31. 10.1039/D0BM02064H10.1039/D0BM02064H ↗
32. 10.1021/acs.nanolett.3c0309810.1021/acs.nanolett.3c03098 ↗
33. 10.1016/j.biomaterials.2021.12089710.1016/j.biomaterials.2021.120897 ↗
34. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
35. 10.1016/j.jconrel.2009.09.01010.1016/j.jconrel.2009.09.010 ↗
36. 10.1016/j.biomaterials.2022.12174610.1016/j.biomaterials.2022.121746 ↗
37. 10.1021/acsami.6b1373810.1021/acsami.6b13738 ↗
38. 10.1016/j.carbpol.2023.12101810.1016/j.carbpol.2023.121018 ↗
39. Eliaz R. E. · Cancer Res. · 2001 · 61 · 2592
40. 10.1021/acs.nanolett.0c0004710.1021/acs.nanolett.0c00047 ↗
41. 10.1002/advs.20230287210.1002/advs.202302872 ↗
42. 10.1016/j.bioactmat.2021.06.03510.1016/j.bioactmat.2021.06.035 ↗
43. 10.1021/acsnano.8b0586010.1021/acsnano.8b05860 ↗
44. 10.1002/advs.20210259510.1002/advs.202102595 ↗
45. 10.1016/j.biomaterials.2022.12170010.1016/j.biomaterials.2022.121700 ↗
46. 10.1002/smll.20140069810.1002/smll.201400698 ↗
47. 10.1186/1475-2875-13-35910.1186/1475-2875-13-359 ↗
48. 10.1002/adfm.20180670810.1002/adfm.201806708 ↗
49. 10.1002/adhm.20220301910.1002/adhm.202203019 ↗
50. 10.2174/092986732366616031612504810.2174/0929867323666160316125048 ↗
51. 10.1016/j.molcel.2017.05.02010.1016/j.molcel.2017.05.020 ↗
52. 10.1002/anie.20210925810.1002/anie.202109258 ↗
53. 10.1016/j.biomaterials.2023.12244710.1016/j.biomaterials.2023.122447 ↗
54. 10.1016/S0009-2797(99)00144-110.1016/S0009-2797(99)00144-1 ↗
55. 10.1021/acsami.7b0527810.1021/acsami.7b05278 ↗
56. 10.1039/C8BM01403E10.1039/C8BM01403E ↗
57. 10.1021/acsami.5b1234710.1021/acsami.5b12347 ↗